articleLeukemiaMay 3, 2012HYBRID OA

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Bristol-Myers Squibb (Switzerland) · Tokyo Institute of Technology

PubMed
Indexed incrossrefdatacitepubmed

Abstract

Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes. CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells. Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing…

Citation impact

796
total citations
FWCI
22.17
Percentile
100%
References
32
Citations per year

Authors

20

Topics & keywords

Keywords
  • Cereblon
  • Pomalidomide
  • Lenalidomide
  • Thalidomide
  • Multiple myeloma
  • Cancer research
  • Pharmacology
  • Biology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding